Recognizing the rapid progress and growing importance of the therapeutic application of nuclear medicine, the Nuclear Medicine Europe Therapy Working Group was established to represent this evolving, cutting-edge sector and to highlight the leading role of all players in the industrial value chain of radiopharmaceutical production for the benefit of patients.

The mission of the Therapy Working Group is based on four fundamental pillars:

1.  Support the nuclear medicine industry in delivering innovative therapeutic solutions to healthcare professionals and patients.
2. Establish radioligand therapy (RLT) as a key component among anti-cancer therapies.
3. Promote equal patient access to the medical benefits of RLT across Europe.
4. Make RLT affordable through its cost-efficient use of medical resources

In order to achieve this mission the WG Therapy will welcome and include members from companies representing the different actors of the value chain that contribute to bringing the full medical benefit of radiopharmaceuticals to the patients. This approach maximize the expertise developed within our industry.

The WG Therapy will serve as a reference group for the Nuclear Medicine Europe Executive Committee decisions and actions.

The Working Group develops opinions and positions on therapeutic perspectives and works to ensure that these positions are well recognized and incorporated into key policy documents at both the EU and national levels.

When necessary or advised, the WG Therapy will meet with other working groups to discuss issues of shared relevance and foster synergistic activities.